(800) 526-OPYS Pay my bill Member login
logo
OPYS 10 years
  • Hospital Solutions
    • Emergency Medicine
    • Hospital Medicine
    • Telemedicine
    • Urgent Care
    • Post Acute Care
    • Correctional Medicine
    • Locum Tenens
  • Join our Team
    • Physicians
    • Advanced Practitioners
    • Career Opportunities
  • About OPYS
    • Experienced Group
    • Metrics & Outcomes
    • Throughout the US
    • Quality Patient Care
    • Clinical Performance
    • Qualified Providers
    • Company Profile
    • Leadership Team
    • Mission Statement
    • Reviews
  • News
  • Contact Us

Migraine Drug Shown for First Time to Provide Long-Term Benefits to Patients

Home > Hospitalists > Migraine Drug Shown for First Time to Provide Long-Term Benefits to Patients

Migraine Drug Shown for First Time to Provide Long-Term Benefits to Patients

July 13, 2021

The drug erenumab has been shown to reduce the frequency of migraines and improve migraine patients’ quality of life in studies that have lasted between 3 and 12 months. However, there has thus far been little research on the long-term effects of this particular therapeutic strategy. Treating migraine is known to be a complex challenge, and people who suffer from migraines are often dissatisfied with the treatments they try because they do not reliably reduce the frequency or intensity of their migraines.

Given the importance of developing therapies with long-term benefits for migraine patients, a new study, published in the European Journal of Neurology, has investigated the effects of erenumab on patients with episodic migraines over a period of 5 years. For the open-label, double-blind, placebo-controlled trial, 383 patients were studied. These patients began on a 70 mg dose of erenumab, which eventually increased to 140 mg. The effects of the treatment were analyzed based on the change in the number of days that migraines were experienced each month, the change in how many days each month the patients had to take medication for their migraines, and any changes in quality of life.

The results showed that erenumab was associated with migraine frequency reductions as well as quality of life improvements that lasted over the 5 year duration during which patients were studied. Specifically, patients experienced improvements related to disability as well as to the impact of their headaches. Patients taking erenumab experienced a reduction in the number of days each month on which they experienced migraines and needed treatment.

Most adverse events were manageable and consisted of nasopharyngitis, influenza, and upper respiratory tract infections. The serious adverse events that occurred in 49 patients tended to involve a single occurrence. However, two patients suffered fatal adverse events.

The findings from this randomized clinical trial demonstrate the potential power of erenumab to provide long-term relief for episodic migraine patients. However, more research is needed to understand the specific impact of this drug on patients and how it could be used by physicians, to safely and effectively treat this group of patients.

 

Reference

Ashina, M. et al. (2021). Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open label treatment phase of a randomized clinical trial. European Journal of Neurology. doi: 10.1111/ene.14715.

Filed Under: Emergency Physicians, General, Hospital Physicians, Hospitalists, Patient Care Tagged With: Emergency Physician, Health care, hospital based physicians, patient care

Search

Categories

  • Best Practice
  • Cardiologists
  • COVID-19
  • Emergency Physicians
  • General
  • Health Technology
  • Hospital Physicians
  • Hospitalists
  • New Job Opportunities
  • Nurses
  • Patient Care
  • Physician Job
  • Physician Services News
  • Public Health
  • Reimbursement
  • Telehealth Blog Series
  • Women's Health

Archives

  • April 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • September 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • December 2017
  • March 2017
  • June 2016
  • August 2015
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011

We’d Love to Hear From You,
Get In Touch With Us!

logo

Since 2012, providing quality, efficient, patient-centered healthcare through experienced medical leadership, communication, and collaboration in the provision of hospital-based physician outsourcing services.

Our Services
  • Emergency Medicine
  • Hospital Medicine
  • Telemedicine
  • Urgent Care
  • Post Acute Care
  • Correctional Medicine
OPYS Advantage
  • Our Team
  • Investor Relations
  • Career Opportunities
Contact
Corporate Office 

One Indiana Square, Suite 2060
Indianapolis, IN 46204

Phone: (800) 526-6797
Fax: (800) 456-6148
Email: info@opys.com

Copyright © 2012 - 2022. All rights reserved I Site Map I Privacy Policy I Terms and Use